Journal of Inherited Metabolic Disease

, Volume 36, Issue 6, pp 1063–1071 | Cite as

High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria

  • Eliane Sardh
  • Staffan Wahlin
  • Mikael Björnstedt
  • Pauline Harper
  • Dan E. H. Andersson
Original Article

Abstract

Background/aims

Previous studies have indicated a high risk of hepatocellular carcinoma in acute hepatic porphyrias. In this retrospective study we present the incidence of primary liver cancer and clinical characteristics in a cohort of 179 acute porphyria patients above the age of 50 years.

Methods

Twenty-three cases with primary liver cancer were found either by a surveillance program or due to clinical suspicion. Standardized rate ratio was used to estimate the relative risk of primary liver cancer after indirect standardization. Survival data were calculated using the Kaplan-Meier method.

Results

The mean age at diagnosis was 69 years. Hepatocellular carcinoma was found in 19 patients while four patients had cholangiocarcinoma or a combination of the two. Four patients had underlying cirrhosis. Mean tumour size was 4.3 cm in the surveillance group and 10.3 cm in the non-surveillance group (p = 0.01). The overall relative risk of primary liver cancer was 86 above the age of 50: 150 for women and 37 for men. Mean survival time was 5.7 years.

Conclusion

Acute hepatic porphyria carries a high risk of primary liver cancer above the age of 50 which warrants ultrasound surveillance. Sex distribution and frequency of cirrhosis differs from more common aetiologies of primary liver cancer.

References

  1. Andant C, Puy H, Bogard C et al (2000) Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 32(6):933–939PubMedCrossRefGoogle Scholar
  2. Anderson KE, Sassa S, Bishop DF, Desnick RJ (2001) Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. The metabolic and molecular bases of inherited disease. In: Scriver CR, Beaudet AL, Sly WS and Valle D (eds) McGraw-Hill, New York 2: 2991–3062Google Scholar
  3. Andersson C, Bjersing L, Lithner F (1996) The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med 240:195–201PubMedCrossRefGoogle Scholar
  4. Batlle AM (1993) Porphyrins, porphyrias, cancer and photodynamic therapy - a model for carcinogenesis. J Photochem Photobiol B Biol 20:5–22CrossRefGoogle Scholar
  5. Bengtsson NO, Hardell L (1986) Porphyrias, porphyrins and hepatocellular cancer. Br J Cancer 54:115–117PubMedCrossRefGoogle Scholar
  6. Bjersing L, Andersson C, Lithner F (1996) Hepatocellular carcinoma in patients from Northern Sweden with acute intermittent porphyria: morphology and mutations. Cancer Epidemiol Biomarkers Prev 5:393–397PubMedGoogle Scholar
  7. Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. J Gastroenterol 127(5):S5–S16CrossRefGoogle Scholar
  8. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236PubMedCrossRefGoogle Scholar
  9. Deybach JC, Puy H (2011) Hepatocellular carcinoma without cirrhosis: think acute hepatic porphyrias and vice versa. J Intern Med 269(5):521–524PubMedCrossRefGoogle Scholar
  10. Floderus Y, Shoolingin-Jordan P, Harper P (2002) Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin Genet 62(4):288–297PubMedCrossRefGoogle Scholar
  11. Hardell L, Bengtsson NO, Jonsson U, Eriksson S, Larsson LG (1984) Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria - an epidemiological investigation. Br J Cancer 50:389–397PubMedCrossRefGoogle Scholar
  12. Harper P, Wahlin S (2007) Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol 10(6):444–455PubMedCrossRefGoogle Scholar
  13. Innala E, Andersson C (2011) Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. J Intern Med 269(5):538–545PubMedCrossRefGoogle Scholar
  14. Kauppinen R, Mustajoki P (1988) Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer 57:117–120PubMedCrossRefGoogle Scholar
  15. Kauppinen R, Mustajoki P (1992) Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 71:1–13PubMedGoogle Scholar
  16. Kauppinen R, von und zu Fraunberg M (2002) Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 48(11):1891–1900PubMedGoogle Scholar
  17. Leong TY, Leong AS (2005) Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) 7(1):5–15CrossRefGoogle Scholar
  18. Lindstedt G, Nillroth LW, von Schéele C, Schelin U, Swolin B, Zettergren L (1973) [Late first appearance of porphyria in a patient with primary liver cancer] Sen debut av porfyri hos en patient med primär levercancer. Lakartidningen 70(47):4265–4266PubMedGoogle Scholar
  19. Lithner F, Wetterberg L (1984) Hepatocelluar carcinoma in patients with acute intermittent porphyria. Acta Med Scand 215:271–274PubMedCrossRefGoogle Scholar
  20. Onuki J, Teixeira PC, Medeiros MH et al (2002) Is 5-aminolevulinic acid involved in the hepatocellular carcinogenesis of acute intermittent porphyria? Cell Mol Biol (Noisy-le-grand) 48(1):17–26Google Scholar
  21. Ostrowski J, Kostrzewska E, Michalak T, Zawirska B, Medrzejewski W, Gregor A (1983) Abnormalities in liver function and morphology and impaired aminopyrine metabolism in hereditary hepatic porphyrias. Gastroenterology 85:1131–1137PubMedGoogle Scholar
  22. Schneider-Yin X, Van Tuyll van Serooskerken AM, Went P et al (2010) Hepatocellular carcinoma in variegate porphyria: a serious complication. Acta Derm Venereol 90(5):512–515PubMedCrossRefGoogle Scholar
  23. Seth AK, Badminton MN, Mirza D, Russell S, Elias E (2007) Liver transplantation for porphyria: who, when, and how? Liver Transpl 13(9):1219–1227PubMedCrossRefGoogle Scholar
  24. Soonawalla ZF, Orug T, Badminton MN et al (2004) Liver transplantation as a cure for acute intermittent porphyria. Lancet 363(9410):705–706PubMedCrossRefGoogle Scholar
  25. Stojeba N, Meyer C, Jeanpierre C et al (2004) Recovery from a variegate porphyria by a liver transplantation. Liver Transpl 10(7):935–938PubMedCrossRefGoogle Scholar
  26. Thunell S, Andersson C, Carlmark B et al (1995) Markers for vulnerability in acute porphyria. A hypothesis paper. Eur J Clin Chem Clin Biochem 33:179–194PubMedGoogle Scholar
  27. Thunell S, Floderus Y, Henrichson A, Harper P (2006) Porphyria in Sweden. Physiol Res 55(Suppl 2):S109–S118PubMedGoogle Scholar
  28. Wahlin S, Harper P, Sardh E, Andersson C, Andersson DE, Ericzon BG (2010) Combined liver and kidney transplantation in acute intermittent porphyria. Transpl Int 23(6):e18–e21PubMedCrossRefGoogle Scholar
  29. Wiman Å (2003) Genetic Characterization of Swedish Families with Hereditary Coproporphyria, Variegate Porphyria, and Erythropoietic Protoporphyria. Dep Med Lab Sci and Tech, Div Clin Chem, Karolinska Institutet, Huddinge Univ Hospital. Stockholm, Karolinska InstitutetGoogle Scholar

Copyright information

© SSIEM and Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Eliane Sardh
    • 1
    • 2
  • Staffan Wahlin
    • 3
  • Mikael Björnstedt
    • 4
  • Pauline Harper
    • 2
  • Dan E. H. Andersson
    • 1
  1. 1.Department of Internal MedicineKarolinska Institutet, Stockholm South HospitalStockholmSweden
  2. 2.Porphyria Centre Sweden, Department of Laboratory MedicineKarolinska Institutet, Karolinska University HospitalStockholmSweden
  3. 3.Department of Gastroenterology and HepatologyKarolinska Institutet, Karolinska University HospitalStockholmSweden
  4. 4.Division of Pathology, Department of Laboratory MedicineKarolinska Institutet, Karolinska University HospitalStockholmSweden

Personalised recommendations